AU8605598A - Targeted hsv vectors - Google Patents

Targeted hsv vectors

Info

Publication number
AU8605598A
AU8605598A AU86055/98A AU8605598A AU8605598A AU 8605598 A AU8605598 A AU 8605598A AU 86055/98 A AU86055/98 A AU 86055/98A AU 8605598 A AU8605598 A AU 8605598A AU 8605598 A AU8605598 A AU 8605598A
Authority
AU
Australia
Prior art keywords
hsv vectors
targeted hsv
targeted
vectors
hsv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU86055/98A
Inventor
Joseph C. Glorioso
Sylvie Laquerre
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pittsburgh
Original Assignee
University of Pittsburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pittsburgh filed Critical University of Pittsburgh
Publication of AU8605598A publication Critical patent/AU8605598A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
AU86055/98A 1997-07-31 1998-07-31 Targeted hsv vectors Abandoned AU8605598A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5432997P 1997-07-31 1997-07-31
US60054329 1997-07-31
PCT/US1998/016051 WO1999006583A1 (en) 1997-07-31 1998-07-31 Targeted hsv vectors

Publications (1)

Publication Number Publication Date
AU8605598A true AU8605598A (en) 1999-02-22

Family

ID=21990309

Family Applications (1)

Application Number Title Priority Date Filing Date
AU86055/98A Abandoned AU8605598A (en) 1997-07-31 1998-07-31 Targeted hsv vectors

Country Status (3)

Country Link
EP (1) EP1002119A1 (en)
AU (1) AU8605598A (en)
WO (1) WO1999006583A1 (en)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6673602B1 (en) 1999-06-11 2004-01-06 The General Hospital Corporation Herpes simplex virus amplicon vector targeting system and method of using same
WO2000077167A2 (en) * 1999-06-11 2000-12-21 The General Hospital Corporation Herpes simplex virus amplicon vector targeting system and method of using same
GB0203285D0 (en) * 2002-02-12 2002-03-27 Brown Susanne M An herpes simplex virus complex
US7550148B2 (en) * 2002-10-07 2009-06-23 The University Of Chicago Targeting of Herpes simplex virus to specific receptors
WO2004033639A2 (en) * 2002-10-07 2004-04-22 University Of Chicago Targeting of herpes simplex virus to specific receptors
US8927251B2 (en) 2002-10-07 2015-01-06 The University Of Chicago Targeting of herpes simplex virus to specific receptors
US20040166091A1 (en) 2003-02-24 2004-08-26 Genvec, Inc. Materials and methods for treating disorders of the ear
GB0317511D0 (en) 2003-07-25 2003-08-27 Biovex Ltd Viral vectors
KR20070100241A (en) 2004-10-28 2007-10-10 유니버시티 오브 피츠버그 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 Peripherally delivered glutamic acid decarboxylase gene therapy for spinal cord injury pain
WO2006132925A2 (en) 2005-06-01 2006-12-14 University Of Pittsburgh Of The Commonwealth System Of Higher Education Method of amidated peptide biosynthesis and delivery in vivo: endomorphin-2 for pain therapy
US20080289058A1 (en) 2007-05-14 2008-11-20 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Targeted delivery of glycine receptors to excitable cells
US20120219583A1 (en) 2009-10-16 2012-08-30 Los Alamos National Security, Llc Nucleic acid sequences encoding expandable hiv mosaic proteins
JP2013527753A (en) 2010-03-23 2013-07-04 イントレキソン コーポレーション Vectors that conditionally express therapeutic proteins, host cells containing the vectors, and uses thereof
WO2011130749A2 (en) 2010-04-16 2011-10-20 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Identification of mutations in herpes simplex virus envelope glycoproteins that enable or enhance vector retargeting to novel non-hsv receptors
JP6189754B2 (en) 2011-03-04 2017-08-30 イントレキソン コーポレーション Vectors that conditionally express proteins
CN113278653A (en) 2013-07-17 2021-08-20 匹兹堡大学-属高等教育联邦体系 Non-toxic HSV vectors for efficient gene delivery applications and complementing cells for their production
US10201575B2 (en) 2013-10-28 2019-02-12 University of Pittsburgh—of the Commonwealth System of Higher Education Oncolytic HSV vector
US9580699B2 (en) 2014-04-17 2017-02-28 University of Pittsburgh—of the Commonwealth System of Higher Education TRPV1 modulatory gene product that affects TRPV1-specific pain behavioral responses identified in a functional screen of an HSV-based cDNA library
MX2017002933A (en) 2014-09-07 2017-05-30 Selecta Biosciences Inc Methods and compositions for attenuating gene editing anti-viral transfer vector immune responses.
TWI710635B (en) 2014-10-09 2020-11-21 美商珍維克公司 Adenoviral vector encoding human atonal homolog-1 (hath1)
SG11201806134SA (en) 2016-01-27 2018-08-30 Oncorus Inc Oncolytic viral vectors and uses thereof
AU2017276723B2 (en) * 2016-06-09 2023-10-05 Alma Mater Studiorum Universita Di Bologna Herpesvirus with modified glycoprotein B
AU2017290828A1 (en) 2016-06-30 2019-01-24 Virogin Biotech Canada Ltd Pseudotyped oncolytic viral delivery of therapeutic polypeptides
CA3034094A1 (en) 2016-08-16 2018-02-22 Bluebird Bio, Inc. Il-10 receptor alpha homing endonuclease variants, compositions, and methods of use
US20190262398A1 (en) 2016-08-23 2019-08-29 Bluebird Bio, Inc. Tim3 homing endonuclease variants, compositions, and methods of use
KR102451510B1 (en) 2016-09-08 2022-10-07 2세븐티 바이오, 인코포레이티드 PD-1 Homing Endonuclease Variants, Compositions and Methods of Use
EP3526334A4 (en) 2016-10-17 2020-09-30 Bluebird Bio, Inc. Tgfbetar2 endonuclease variants, compositions, and methods of use
EP4353822A3 (en) 2016-11-17 2024-07-03 2seventy bio, Inc. Tgf beta signal convertor
US20180193482A1 (en) 2017-01-07 2018-07-12 Selecta Biosciences, Inc. Patterned dosing of immunosuppressants coupled to synthetic nanocarriers
WO2018152325A1 (en) 2017-02-15 2018-08-23 Bluebird Bio, Inc. Donor repair templates multiplex genome editing
IL269534B1 (en) 2017-03-30 2024-09-01 Univ Queensland Chimeric molecules and uses thereof
US20210147818A1 (en) 2017-05-25 2021-05-20 Bluebird Bio, Inc. Cblb endonuclease variants, compositions, and methods of use
CA3070299A1 (en) 2017-07-26 2019-01-31 Oncorus, Inc. Oncolytic viral vectors and uses thereof
US12076369B2 (en) 2017-09-01 2024-09-03 The Frances Crick Institute Limited Immunoregulatory molecules and uses therefor
WO2019070974A1 (en) 2017-10-04 2019-04-11 Bluebird Bio, Inc. Pcsk9 endonuclease variants, compositions, and methods of use
AU2018347583A1 (en) 2017-10-13 2020-05-21 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector IgM responses
US11865081B2 (en) 2017-12-29 2024-01-09 Virogin Biotech Canada Ltd. Oncolytic viral delivery of therapeutic polypeptides
CA3092372A1 (en) 2018-02-26 2019-08-29 AnTolRx, Inc. Tolerogenic liposomes and methods of use thereof
IL279310B2 (en) 2018-06-14 2024-09-01 Bluebird Bio Inc Cd79a chimeric antigen receptors
WO2020072059A1 (en) 2018-10-04 2020-04-09 Bluebird Bio, Inc. Cblb endonuclease variants, compositions, and methods of use
EP3962537A1 (en) 2019-04-28 2022-03-09 Selecta Biosciences, Inc. Methods for treatment of subjects with preexisting immunity to viral transfer vectors
CA3141863A1 (en) 2019-05-28 2020-12-03 Selecta Biosciences, Inc. Methods and compositions for attenuated anti-viral transfer vector immune response
KR20220078650A (en) 2019-10-10 2022-06-10 온코루스, 인크. Double virus and double oncolytic virus and treatment methods
BR112022020444A2 (en) 2020-04-10 2022-11-29 Sola Biosciences Llc COMPOSITIONS AND METHODS FOR THE TREATMENT OF PROTEIN AGGREGATION DISORDERS
BR112022021604A2 (en) 2020-04-28 2022-12-06 Sola Biosciences Llc COMPOSITIONS AND METHODS FOR TREATMENT OF PROTEINOPATHIES ASSOCIATED WITH TDP-43
JP2023529371A (en) 2020-06-05 2023-07-10 ソラ・バイオサイエンシズ・エルエルシー Compositions and methods for the treatment of synucleinopathies
IL298853A (en) 2020-06-09 2023-02-01 Inozyme Pharma Inc Soluble enpp1 or enpp3 proteins and uses thereof
EP4232462A1 (en) 2020-10-26 2023-08-30 SOLA Biosciences LLC Compositions and methods for the treatment of alzheimer's disease
WO2023288267A1 (en) 2021-07-14 2023-01-19 2Seventy Bio, Inc. Engineered t cell receptors fused to binding domains from antibodies
EP4413024A2 (en) 2021-10-08 2024-08-14 SOLA Biosciences LLC Compositions and methods for the treatment of proteopathies
CA3234720A1 (en) 2021-10-08 2023-04-13 Sola Biosciences Llc Compositions and methods for the treatment of p53-mediated cancers
WO2023064367A1 (en) 2021-10-12 2023-04-20 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector igm responses
WO2023172624A1 (en) 2022-03-09 2023-09-14 Selecta Biosciences, Inc. Immunosuppressants in combination with anti-igm agents and related dosing
WO2023196997A2 (en) 2022-04-08 2023-10-12 2Seventy Bio, Inc. Multipartite receptor and signaling complexes

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9223084D0 (en) * 1992-11-04 1992-12-16 Imp Cancer Res Tech Compounds to target cells
EP0840797B1 (en) * 1995-07-25 2014-09-03 Crucell Holland B.V. Methods and means for targeted gene delivery

Also Published As

Publication number Publication date
EP1002119A1 (en) 2000-05-24
WO1999006583A1 (en) 1999-02-11

Similar Documents

Publication Publication Date Title
AU8605598A (en) Targeted hsv vectors
AU1709299A (en) Mixer-injectors
AU8921698A (en) Follistatin-3
AU9414098A (en) Ascorbyl-phosphoryl-cholesterol
AU5566598A (en) Hydrogels
AU6598798A (en) Resorcinyl-triazines
AU1027499A (en) 32P-polyphosphazene
AU9513298A (en) Fluoranthenopyrans
AU5272198A (en) EMP-charge-eliminator
AU4117497A (en) Micropolarimeter
AU6185898A (en) Clavaspirins
AU1999999A (en) Contryphan peptides
AU6525998A (en) Improved metallo-endopeptidases
AU7761998A (en) Korrosionsschutzanstrichstoff
AU8214598A (en) 3-benzylpiperidine
AU9183798A (en) Catamaran - bicycle - kayak
AU8991998A (en) Renovative pipeliner
AU4469997A (en) Heregulin-gamma
AU5391798A (en) Thiamacrolides
AU5540298A (en) Rockbolts
AU6060598A (en) Multi-hopper
AU6507298A (en) Renovative pipeliner
AU6237398A (en) N-het-substituted glycerophosphoethanolamines
AU8121298A (en) G-seat
AU7780498A (en) Cafetiere

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase